Background: Cardiotoxicity development in survivors of acute lymphoblastic leukemia is one of the most serious chronic complications of cancer therapy. This study aimed to assess the frequency of doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Methods: We utilized a crosssection case-control study design and included 50 ALL survivors attending a pediatric oncology clinic for follow-up after finishing chemotherapy and 50 age- and sex-matched controls. All participants were subjected to a full general examination. The cardiac status was assessed by Echocardiography and Tissue Doppler Technique. Results: Tissue doppler parameters S" (myocardial systolic velocity) m/sec, E" (early phase of diastole negative velocity) and A” m/sec (late phase of diastole negative velocity), A (peak early mitral inflow velocity), and E (peak late mitral inflow velocity) wave DT(deceleration time), GCS(global circumferential strain) &GLS(global longitudinal strain) were statistically lower among ALL survivor than controls, but MPI(myocardial performance index) was statistically higher among ALL survivor than controls. Conclusions: Our results demonstrated that all echocardiographic and Tissue Doppler parameters are lower among ALL survivors than controls, except that MPI(myocardial performance index), LVED (left ventricular end-diastolic dimension), and LVES(left ventricular end-systolic dimension) is higher among ALL survivors than controls indicating cardiac dysfunction among ALL survivors